On Tuesday, Novartis increased its full-year earnings estimates amid robust drug sales and stated plans for the stock market debut of Sandoz.
Its stock price went up by 0.11% to $98.94 per share on Monday. The launch of its generic medicines sector would be in early October.
The Swiss drugmaker anticipated growth for its group’s core operating profits. It expects a low double-digit improvement from the high single-digit growth previously.
Novartis shareholders agreed to have the proposed Sandoz spin-off and total separation at a meeting on September 15.
Experts said a listing on the SIX Swiss Exchange and an American Depositary Receipt program would come the following month.
Moreover, its Q2 sales jumped by 7.00% to $13.60 billion, higher than analysts estimated $13.20 billion. Likewise, its adjusted operating profit rose by 9.00% to $4.67 billion, topping the $4.30 billion consensus.
Its gains were led by higher-than-expected sales of Entresto, its heart failure drug, up by 37.00% to $1.52 billion. Furthermore, Novartis is in a legal battle with generic drugmakers to release more affordable copies before Entresto’s patent protection ends.
For Kesimpta and Pluvicto, both drugs from Novartis also increased earnings.
On the other hand, Sandoz would have a low-to-mid single-digit billion-dollar worth of net financial debt. It matches with a BBB investment grade financial rating.
DTx Pharma Acquired by Novartis
DTx Pharma, a San Diego, CA-based biotechnology company, was acquired by Novartis for approximately one billion dollars.
The Swiss drugmaker will directly pay $500.00 million plus additional payments of the same amount. These are requirements for the completion of the movement.
Also, the contract includes DTx-1252 to potentially deliver a transformative medicine. It would target Charcot-Marie-Tooth Disease Type 1A and early-stage programs for neuromuscular and CNS indications.
According to DTx Pharma Officer Peter Condon, the team from Novartis has sufficient knowledge about patients’ situations. As a result, they look forward to working with them to develop their transformative medicine.
Moreover, the deal solidifies its platform’s validation and capability to open new therapeutic areas beyond the liver.